Who Should Be Immunized

BioThrax^® (Anthrax Vaccine Adsorbed) is indicated for individuals between 18 and 65 years of age at high risk of exposure to anthrax. BioThrax is not licensed for use in a post-exposure setting. The safety and efficacy of BioThrax have not been established in pregnant women, nursing mothers, pediatric populations or geriatric populations.

To date, more than 8.7 million doses of BioThrax have been administered to more than 2.2 million individuals.

The best way to protect against infectious diseases is to get vaccinated before exposure. A vaccine is currently available for pre-exposure protection against anthrax. It is called BioThrax.

BioThrax may not protect all individuals vaccinated, particularly patients with impaired immune responses due to congenital or acquired immunodeficiency, or immunosuppressive therapy. Individuals are not considered protected until they have completed the full vaccination series.